Navigation Links
Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
Date:11/2/2009

. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ material
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHAPEL HILL, N.C. , Jan. 23, 2015 For ... organizations are in dealing with payers. Likewise, the importance of ... payers - will only continue to grow as payer formularies ... patients access therapies. At the same time, managed ...
(Date:1/23/2015)... LOS ANGELES , Jan. 23, 2015 A lot ... the best methods for treating  certain illnesses, injuries, or conditions. ... to replace previous treatment methods with ones that they consider ... treating hernias, there is not one textbook method of treatment ...
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... A milestone in lupus research was met this weekend!  On ... held its 8th annual New York City Walk with Us ... matched by the enthusiasm of the nearly 3000 walkers in attendance ... master of ceremonies, My9 news anchor Brenda Blackmon, ALR Chairman Robert ...
... LOUIS, Oct. 27, 2011 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November: Credit Suisse 2011 ... mountain (9:30 a.m. eastern). Lazard Capital Markets, 8th ... a.m. eastern. These presentations will also be ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... macular degeneration (AMD)including an intravitreous (into the eye) injection ... compound approved for use against the eye diseasedo not ... cardiovascular complications or death when compared with existing therapies, ... Archives of Ophthalmology , one of the JAMA/Archives ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... your dog home alone without having to worry about chewed ... how to look at the sunny side of life. ... more likely to become distressed and anxious when left alone ...
... , SUNDAY, Oct. 10 (HealthDay News) -- Scientists have found ... for obesity. The findings are reported in two new ... Nature Genetics . , In one report, researchers say they ... the involvement of 14 others. In a second report, the ...
... 2010 A clinical trial at UT Southwestern Medical ... to standard insulin therapy might help rein in the ... diabetes. This is the first type 1 diabetes ... fat cells and involved in body-weight regulation. For this ...
... and structured weight loss programs, can result in significant weight ... two reports that were posted online today by JAMA ... early online to coincide with the presentation of these papers ... The articles will appear in the October 27 print ...
... at UT Southwestern Medical Center have created an experimental ... in the brain and is believed to contribute to ... similar so-called DNA vaccines that the UT Southwestern researchers ... stimulated more than 10 times as many antibodies that ...
Cached Medicine News:Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 3Health News:Researchers Pinpoint Array of Obesity Genes 2Health News:Researchers Pinpoint Array of Obesity Genes 3Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 2Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 3Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 2Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 3Health News:UT Southwestern researchers create experimental vaccine against Alzheimer's 2
The Thrombex PMT system is a self-contained, disposable clot-removal device that uses a motor-driven catheter and vacuum source to break up and remove thrombi from a hemodialysis graft....
... AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is designed ... Powerful saline jets create a low pressure ... vacuum effect. Thrombus is drawn into the ... jets, and removed from the body.,AngioJet thrombectomy ...
... pulse generators are meeting the clinical ... electrophysiologists and anesthesiologists. And, they are ... expect from Medtronic.,Effective pacing with the ... polarity for quick battery changes. ...
... St. Jude Medical offers the world's ... Pacel bipolar pacing catheters are available in ... a broad range of curve choices and ... Pacing Catheter is indicated for use in ...
Medicine Products: